On August 28, 2018 INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, reported that its co-founder and CEO, Raymond J. Tesi, M.D., will participate in a panel at the Immuno-Oncology Investing & Partnering Forum on Aug. 30. He will also chair a session and present at the 2nd Annual Emerging Immuno-Oncology Targets Conference on August 31 (Press release, INmune Bio, AUG 28, 2018, View Source [SID1234529238]). Both conferences will take place in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is a privilege to present to many of the leading minds in immunotherapy from both academia and industry," said Dr. Tesi. "Understanding why some patients are resistant to immunotherapy is vital as immunotherapy becomes the backbone of cancer treatment. We believe reprogramming the innate system to allow for more effective immunotherapy is key to solving this problem."
During Dr. Tesi’s panel at the Immuno-Oncology Investing & Partnering Forum, titled "Novel Therapeutics in Cancer Immunotherapy," he will discuss new immunotherapy drugs and therapeutic strategies in an attempt to highlight new approaches in the field.
The inaugural Immuno-Oncology Investing & Partnering Forum will be hosted by Cambridge Healthtech Institute as part of the Immuno-Oncology Summit. The forum brings together early and late-stage investors, fundraising CEOs and research entrepreneurs to encourage partnering and investment and to boost the immunotherapy market.
At the Emerging Immuno-Oncology Targets Conference, Dr. Tesi will present "Targeting Soluble TNF in Tumor Microenvironment (TME) to Reverse Resistance to Immunotherapy." His talk will highlight the role of chronic inflammation as a cause for failed checkpoint inhibitor therapies and will discuss how neutralizing soluble tumor necrosis factor (TNF) in the TME can target MDSC, a major cause of resistance to checkpoint inhibitors and other immunotherapies.
The Emerging Immuno-Oncology Targets conference, also hosted by Cambridge Healthtech Institute, covers the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy.
Details of the presentations are as follows:
Immuno-Oncology Investing & Partnering Forum
Session Title: Novel Therapeutics in Cancer Immunotherapy
Date and Time: August 30, 2018, at 1:30 p.m.
Location: Seaport World Trade Center, Boston, Massachusetts
Emerging Immuno-Oncology Targets
Title: Emerging Cytokine Targets
Session Title: Targeting Soluble TNF in Tumor Microenvironment (TME) to Reverse Resistance to Immunotherapy
Date and Time: August 31, 2018, at 9:05 a.m.
Location: Seaport World Trade Center, Boston, Massachusetts